Company: INTS
Filing Date: 2025-03-28
Form Type: DRS
Source: 0001628279-25-000170
Chunk: 43

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-28
Form: DRS
Chunk 43
---
 carry over to the share of Common Stock received upon exercise, increased by the exercise price of $0.0001. Each holder should consult his, her or its own tax advisor regarding the risks associated with the acquisition of Pre-Funded Warrants pursuant to this offering (including potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.

In certain circumstances, the Pre-Funded Warrants may be exercised on a cashless basis. The U.S. federal income tax treatment of a cashless exercise of Pre-Funded Warrants into Common Stock is unclear, and the tax consequences of a cashless exercise could differ from the consequences upon the exercise of a Pre-Funded Warrant described in the preceding paragraph. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of a cashless exercise of Pre-Funded Warrants.

Material U.S. Federal Income Tax Considerations of Owning and Disposing of Common Stock, Pre-Funded Warrants, or Common Warrants for U.S. Holders

The following discusses the material U.S. federal income tax consideration of owning and disposing of our Common Stock, Pre-Funded Warrants or Common Warrants for a U.S. holder. This section does not address the U.S. federal income tax considerations for U.S. holders of backup withholding and information reporting.

For purposes of this discussion, a “U.S. holder” is any beneficial owner of our Common Stock, Pre-Funded Warrants or Common Warrants that, for U.S. federal income tax purposes, is:

• an individual who is a citizen or resident of the United States;

• a domestic corporation;

• an estate, the income of which is subject to U.S. federal income tax regardless of its source; or

<div align='center'>28

Confidential Treatment Requested by Intensity Therapeutics, Inc.</div>

#### Pursuant to 17 C.F.R. Section 200.83
• a trust, if (A) a U.S. court is able to exercise primary supervision over the trust’s administration and one or more U.S. persons have authority to control all of the trust’s substantial decisions or (B) the trust has validly elected to be treated as a U.S. person for U.S. federal income tax purposes.

Allocation of Purchase Price Between Common Stock or Pre-Funded Warrants and Common Warrants

Because our Common Stock and accompanying Common Warrants, or Pre-Funded